Cargando…
Can regulatory T cells improve outcomes of sensitised patients after HLA-Ab incompatible renal transplantation: study protocol for the Phase IIa GAMECHANgER-1 trial
BACKGROUND: Kidney transplantation is the gold-standard treatment for patients with kidney failure. However, one-third of patients awaiting a kidney transplant are highly sensitized to human leukocyte antigens (HLA), resulting in an increased waiting time for a suitable kidney, more acute and chroni...
Autores principales: | Dudreuilh, C, Jarvis, P, Beadle, N, Pilecka, I, Shaw, O, Gardner, L, Scottà, C, Mamode , N, Game, DS, Sanchez-Fueyo, A, Lombardi, G, Learoyd, A, Douiri, A, Dorling, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140710/ https://www.ncbi.nlm.nih.gov/pubmed/37118685 http://dx.doi.org/10.1186/s12882-023-03157-7 |
Ejemplares similares
-
Gamechangers
Publicado: (2016) -
Gamechangers
Publicado: (2015) -
Gamechangers
Publicado: (2016) -
Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation
por: Dudreuilh, Caroline, et al.
Publicado: (2021) -
WILL SGLT2 INHIBITORS PROVE TO BE A ‘MULTIPLE’ GAMECHANGER?
por: Sharkey, Noel, et al.
Publicado: (2019)